HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Larson, S. M. Articles by Williams, D. L. Search for Related Content PubMed PubMed Citation Articles by Larson, S. M. Articles by Williams, D. L.

Positron Imaging Feasibility Studies. I: Characteristics of [³H]Thymidine Uptake in Rodent and Canine Neoplasms: Concise Communication

VA Medical Center, Fred Hutchinson Cancer Research Center, and University of Washington, Seattle, Washington

Correspondence: For reprints contact: Steven M. Larson, MD, Nuclear Medicine Section (115), VA Medical Center, 4435 Beacon Ave. S., Seattle, WA 98108.

ABSTRACT

Uptake [³H]thymidine was studied in BALB/c mice with EMT-6 sarcoma, in Buffalo rats with Morris 7777 hepatoma, and in nine dogs with spontaneous neoplasms: four lymphomas, two osteosarcomas, two soft-tissue sarcomas, and a thyroid carcinoma. High tumor-to-tissue ratios were observed for all tumor types assayed, and absolute uptakes, when computed as percent dose per gram tumor normalized for body weight, were similar for transplanted and spontaneous tumors. In the rodent tumors, radiothymidine was retained for at least 3 hr in the tumor without appreciable loss. In canine neoplasms, although the highest uptakes were observed in cellular tumors with many mitotic figures, tumor uptake showed significant variability that did not correlate with any obvious histologic change, and thus may reflect true biologic differences in metabolism among tumors at different sites in the same animal. These studies provide additional experimental evidence that the ratios of neoplastic to normal tissue and the kinetics of thymidine uptake by tumors are suitable for positron emission tomography of neoplasms in small and large animals, including both transplanted and spontaneous tumors.

This article has been cited by other articles:

				J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF]

				M. Muzi, H. Vesselle, J. R. Grierson, D. A. Mankoff, R. A. Schmidt, L. Peterson, J. M. Wells, and K. A. Krohn Kinetic Analysis of 3'-Deoxy-3'-Fluorothymidine PET Studies: Validation Studies in Patients with Lung Cancer J. Nucl. Med., February 1, 2005; 46(2): 274 - 282. [Abstract] [Full Text] [PDF]

				M. Muzi, D. A. Mankoff, J. R. Grierson, J. M. Wells, H. Vesselle, and K. A. Krohn Kinetic Modeling of 3'-Deoxy-3'-Fluorothymidine in Somatic Tumors: Mathematical Studies J. Nucl. Med., February 1, 2005; 46(2): 371 - 380. [Abstract] [Full Text] [PDF]

				R. G. Blasberg, U. Roelcke, R. Weinreich, B. Beattie, K. von Ammon, Y. Yonekawa, H. Landolt, I. Guenther, N. E. A. Crompton, P. Vontobel, et al. Imaging Brain Tumor Proliferative Activity with [124I]Iododeoxyuridine Cancer Res., February 1, 2000; 60(3): 624 - 635. [Abstract] [Full Text]

				J. F. Eary, D. A. Mankoff, A. M. Spence, M. S. Berger, A. Olshen, J. M. Link, F. O'Sullivan, and K. A. Krohn 2-[C-11]Thymidine Imaging of Malignant Brain Tumors Cancer Res., February 1, 1999; 59(3): 615 - 621. [Abstract] [Full Text] [PDF]